Stem definition | Drug id | CAS RN |
---|---|---|
dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors | 1567 | 59-92-7 |
Dose | Unit | Route |
---|---|---|
3.50 | g | O |
0.60 | g | O |
0.45 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1.65 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 674.47 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 41 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.70 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 23 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.76 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 19, 2019 | EMA | Acorda Therapeutics Ireland Limited | |
June 4, 1970 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dyskinesia | 385.17 | 15.66 | 168 | 11697 | 27693 | 50565566 |
Hallucination | 218.36 | 15.66 | 136 | 11729 | 46521 | 50546738 |
Hallucination, visual | 172.15 | 15.66 | 82 | 11783 | 16500 | 50576759 |
On and off phenomenon | 166.67 | 15.66 | 43 | 11822 | 1369 | 50591890 |
Parkinson's disease | 163.77 | 15.66 | 41 | 11824 | 1154 | 50592105 |
Muscle rigidity | 157.89 | 15.66 | 66 | 11799 | 9763 | 50583496 |
Impulse-control disorder | 154.43 | 15.66 | 35 | 11830 | 635 | 50592624 |
Freezing phenomenon | 120.23 | 15.66 | 31 | 11834 | 984 | 50592275 |
Bradykinesia | 115.47 | 15.66 | 41 | 11824 | 3902 | 50589357 |
Neuroleptic malignant syndrome | 115.37 | 15.66 | 55 | 11810 | 11075 | 50582184 |
Delirium | 113.24 | 15.66 | 84 | 11781 | 38108 | 50555151 |
Tremor | 108.39 | 15.66 | 134 | 11731 | 114769 | 50478490 |
Compulsive shopping | 100.21 | 15.66 | 25 | 11840 | 693 | 50592566 |
Delusion | 93.87 | 15.66 | 47 | 11818 | 10522 | 50582737 |
Pleurothotonus | 89.91 | 15.66 | 26 | 11839 | 1275 | 50591984 |
Dopamine dysregulation syndrome | 79.42 | 15.66 | 16 | 11849 | 160 | 50593099 |
Stereotypy | 77.56 | 15.66 | 18 | 11847 | 364 | 50592895 |
Parkinsonism | 74.63 | 15.66 | 38 | 11827 | 8809 | 50584450 |
Sudden onset of sleep | 66.69 | 15.66 | 17 | 11848 | 515 | 50592744 |
Dementia | 65.70 | 15.66 | 43 | 11822 | 15954 | 50577305 |
Akinesia | 61.20 | 15.66 | 20 | 11845 | 1479 | 50591780 |
Fall | 60.55 | 15.66 | 194 | 11671 | 334738 | 50258521 |
Stoma site discharge | 60.20 | 15.66 | 19 | 11846 | 1256 | 50592003 |
Dystonia | 58.83 | 15.66 | 36 | 11829 | 11890 | 50581369 |
Gambling disorder | 57.24 | 15.66 | 18 | 11847 | 1176 | 50592083 |
Dropped head syndrome | 55.74 | 15.66 | 11 | 11854 | 98 | 50593161 |
Abnormal behaviour | 55.47 | 15.66 | 42 | 11823 | 19616 | 50573643 |
Torticollis | 54.45 | 15.66 | 19 | 11846 | 1717 | 50591542 |
Myoclonus | 50.12 | 15.66 | 35 | 11830 | 14435 | 50578824 |
Hyperkinesia | 49.84 | 15.66 | 17 | 11848 | 1435 | 50591824 |
Stoma site erythema | 49.33 | 15.66 | 15 | 11850 | 876 | 50592383 |
Fibroma | 47.74 | 15.66 | 14 | 11851 | 721 | 50592538 |
Orthostatic hypotension | 46.28 | 15.66 | 45 | 11820 | 29436 | 50563823 |
Gait disturbance | 45.22 | 15.66 | 105 | 11760 | 149900 | 50443359 |
Camptocormia | 44.62 | 15.66 | 11 | 11854 | 290 | 50592969 |
Speech disorder | 44.44 | 15.66 | 48 | 11817 | 35500 | 50557759 |
Confusional state | 44.34 | 15.66 | 119 | 11746 | 185809 | 50407450 |
Stoma site reaction | 43.00 | 15.66 | 10 | 11855 | 204 | 50593055 |
Reduced facial expression | 40.77 | 15.66 | 15 | 11850 | 1579 | 50591680 |
Product residue present | 40.66 | 15.66 | 19 | 11846 | 3653 | 50589606 |
Agitation | 40.50 | 15.66 | 56 | 11809 | 53328 | 50539931 |
Product complaint | 40.33 | 15.66 | 28 | 11837 | 11438 | 50581821 |
Psychotic disorder | 39.41 | 15.66 | 36 | 11829 | 21776 | 50571483 |
Jealous delusion | 39.32 | 15.66 | 7 | 11858 | 33 | 50593226 |
Stoma site irritation | 39.26 | 15.66 | 9 | 11856 | 172 | 50593087 |
Drug interaction | 39.07 | 15.66 | 119 | 11746 | 199502 | 50393757 |
Ileus | 38.96 | 15.66 | 29 | 11836 | 13200 | 50580059 |
Rash | 38.45 | 15.66 | 28 | 11837 | 437443 | 50155816 |
Therapeutic product effect variable | 38.34 | 15.66 | 13 | 11852 | 1077 | 50592182 |
Joint swelling | 38.06 | 15.66 | 6 | 11859 | 245280 | 50347979 |
Vascular encephalopathy | 37.04 | 15.66 | 10 | 11855 | 380 | 50592879 |
Posture abnormal | 36.83 | 15.66 | 15 | 11850 | 2074 | 50591185 |
Hypersexuality | 35.54 | 15.66 | 10 | 11855 | 444 | 50592815 |
Disorientation | 34.37 | 15.66 | 42 | 11823 | 35442 | 50557817 |
Alopecia | 33.79 | 15.66 | 8 | 11857 | 245039 | 50348220 |
Rheumatoid arthritis | 33.67 | 15.66 | 4 | 11861 | 202546 | 50390713 |
Dysphagia | 33.57 | 15.66 | 63 | 11802 | 77455 | 50515804 |
Aortic valve incompetence | 33.49 | 15.66 | 19 | 11846 | 5457 | 50587802 |
Peripheral swelling | 32.03 | 15.66 | 5 | 11860 | 205931 | 50387328 |
Eczema eyelids | 31.59 | 15.66 | 7 | 11858 | 114 | 50593145 |
Restlessness | 31.47 | 15.66 | 34 | 11831 | 25139 | 50568120 |
Ketonuria | 30.70 | 15.66 | 9 | 11856 | 463 | 50592796 |
Somnolence | 29.93 | 15.66 | 92 | 11773 | 154893 | 50438366 |
Stoma site pain | 29.92 | 15.66 | 10 | 11855 | 793 | 50592466 |
Movement disorder | 29.72 | 15.66 | 28 | 11837 | 17604 | 50575655 |
Tarsal tunnel syndrome | 29.52 | 15.66 | 9 | 11856 | 530 | 50592729 |
Nasopharyngitis | 29.29 | 15.66 | 5 | 11860 | 192922 | 50400337 |
Choking | 28.13 | 15.66 | 20 | 11845 | 8478 | 50584781 |
Heat stroke | 27.96 | 15.66 | 9 | 11856 | 634 | 50592625 |
Hypokinesia | 27.79 | 15.66 | 23 | 11842 | 12194 | 50581065 |
Deep brain stimulation | 27.68 | 15.66 | 5 | 11860 | 26 | 50593233 |
Device difficult to use | 27.61 | 15.66 | 21 | 11844 | 9865 | 50583394 |
Aggression | 27.24 | 15.66 | 29 | 11836 | 21087 | 50572172 |
Oromandibular dystonia | 26.91 | 15.66 | 8 | 11857 | 432 | 50592827 |
Drug withdrawal syndrome | 26.44 | 15.66 | 31 | 11834 | 25050 | 50568209 |
Anxiety | 25.95 | 15.66 | 96 | 11769 | 177510 | 50415749 |
Therapeutic response shortened | 25.88 | 15.66 | 18 | 11847 | 7371 | 50585888 |
Headache | 25.71 | 15.66 | 50 | 11815 | 506485 | 50086774 |
Purpura senile | 25.46 | 15.66 | 8 | 11857 | 521 | 50592738 |
Blood creatine phosphokinase increased | 25.19 | 15.66 | 31 | 11834 | 26336 | 50566923 |
Pruritus | 25.07 | 15.66 | 18 | 11847 | 283550 | 50309709 |
Device issue | 25.01 | 15.66 | 27 | 11838 | 19945 | 50573314 |
Swelling | 24.98 | 15.66 | 8 | 11857 | 200864 | 50392395 |
Hallucination, auditory | 24.00 | 15.66 | 20 | 11845 | 10708 | 50582551 |
Resorption bone increased | 23.97 | 15.66 | 9 | 11856 | 1002 | 50592257 |
Wrong product administered | 23.46 | 15.66 | 15 | 11850 | 5345 | 50587914 |
Depressed level of consciousness | 23.46 | 15.66 | 43 | 11822 | 51910 | 50541349 |
Coma | 23.11 | 15.66 | 45 | 11820 | 56834 | 50536425 |
Pain | 23.09 | 15.66 | 65 | 11800 | 578838 | 50014421 |
Diarrhoea | 22.79 | 15.66 | 67 | 11798 | 588409 | 50004850 |
Paranoia | 22.54 | 15.66 | 19 | 11846 | 10329 | 50582930 |
Psychomotor hyperactivity | 22.18 | 15.66 | 18 | 11847 | 9283 | 50583976 |
Drug hypersensitivity | 22.09 | 15.66 | 16 | 11849 | 250994 | 50342265 |
Vestibular disorder | 21.99 | 15.66 | 9 | 11856 | 1260 | 50591999 |
Device use issue | 21.42 | 15.66 | 10 | 11855 | 1919 | 50591340 |
Retroperitoneal fibrosis | 20.89 | 15.66 | 6 | 11859 | 287 | 50592972 |
Orthostatic intolerance | 20.65 | 15.66 | 8 | 11857 | 970 | 50592289 |
Cognitive disorder | 20.53 | 15.66 | 37 | 11828 | 44086 | 50549173 |
Product use issue | 20.35 | 15.66 | 5 | 11860 | 149470 | 50443789 |
Parkinsonism hyperpyrexia syndrome | 20.31 | 15.66 | 5 | 11860 | 131 | 50593128 |
Hypersensitivity | 19.88 | 15.66 | 13 | 11852 | 215148 | 50378111 |
Application site reaction | 19.70 | 15.66 | 7 | 11858 | 667 | 50592592 |
Progressive supranuclear palsy | 19.19 | 15.66 | 4 | 11861 | 48 | 50593211 |
Coronary artery dissection | 19.18 | 15.66 | 7 | 11858 | 720 | 50592539 |
Cogwheel rigidity | 19.08 | 15.66 | 9 | 11856 | 1768 | 50591491 |
Abdominal discomfort | 18.82 | 15.66 | 16 | 11849 | 231625 | 50361634 |
Completed suicide | 18.77 | 15.66 | 4 | 11861 | 131885 | 50461374 |
Exposure during pregnancy | 18.66 | 15.66 | 3 | 11862 | 121012 | 50472247 |
Product administration error | 18.56 | 15.66 | 23 | 11842 | 19676 | 50573583 |
Cross sensitivity reaction | 18.20 | 15.66 | 9 | 11856 | 1960 | 50591299 |
Infection | 18.05 | 15.66 | 9 | 11856 | 172945 | 50420314 |
Tension | 18.02 | 15.66 | 10 | 11855 | 2752 | 50590507 |
Cerebral atrophy | 17.99 | 15.66 | 12 | 11853 | 4589 | 50588670 |
Treatment failure | 17.98 | 15.66 | 5 | 11860 | 137632 | 50455627 |
Hepatic enzyme increased | 17.93 | 15.66 | 5 | 11860 | 137375 | 50455884 |
Fatigue | 17.60 | 15.66 | 96 | 11769 | 707505 | 49885754 |
Glossodynia | 17.52 | 15.66 | 3 | 11862 | 115566 | 50477693 |
Tongue necrosis | 17.25 | 15.66 | 3 | 11862 | 12 | 50593247 |
Arthropathy | 16.80 | 15.66 | 8 | 11857 | 157898 | 50435361 |
Balance disorder | 16.60 | 15.66 | 45 | 11820 | 70545 | 50522714 |
Nuchal rigidity | 16.57 | 15.66 | 6 | 11859 | 603 | 50592656 |
Ammonia increased | 16.44 | 15.66 | 11 | 11854 | 4230 | 50589029 |
Mobility decreased | 15.92 | 15.66 | 48 | 11817 | 79900 | 50513359 |
Pneumonia aspiration | 15.72 | 15.66 | 27 | 11838 | 30977 | 50562282 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dyskinesia | 374.28 | 15.32 | 178 | 12265 | 19883 | 29542201 |
Gambling disorder | 323.70 | 15.32 | 84 | 12359 | 1491 | 29560593 |
On and off phenomenon | 274.63 | 15.32 | 77 | 12366 | 1851 | 29560233 |
Dopamine dysregulation syndrome | 268.44 | 15.32 | 54 | 12389 | 275 | 29561809 |
Hypersexuality | 262.64 | 15.32 | 69 | 12374 | 1287 | 29560797 |
Hallucination | 239.60 | 15.32 | 177 | 12266 | 44535 | 29517549 |
Impulse-control disorder | 216.60 | 15.32 | 58 | 12385 | 1167 | 29560917 |
Parkinson's disease | 187.66 | 15.32 | 53 | 12390 | 1308 | 29560776 |
Muscle rigidity | 182.96 | 15.32 | 86 | 12357 | 9325 | 29552759 |
Hallucination, visual | 153.03 | 15.32 | 89 | 12354 | 14926 | 29547158 |
Fall | 118.65 | 15.32 | 242 | 12201 | 176936 | 29385148 |
Neuroleptic malignant syndrome | 114.50 | 15.32 | 76 | 12367 | 16072 | 29546012 |
Freezing phenomenon | 107.97 | 15.32 | 34 | 12409 | 1229 | 29560855 |
Bradykinesia | 100.89 | 15.32 | 42 | 12401 | 3405 | 29558679 |
Akinesia | 92.82 | 15.32 | 34 | 12409 | 1956 | 29560128 |
Gambling | 78.95 | 15.32 | 18 | 12425 | 179 | 29561905 |
Dementia | 78.14 | 15.32 | 53 | 12390 | 11605 | 29550479 |
Tremor | 78.04 | 15.32 | 123 | 12320 | 73415 | 29488669 |
Confusional state | 71.96 | 15.32 | 163 | 12280 | 127714 | 29434370 |
Sudden onset of sleep | 71.95 | 15.32 | 19 | 12424 | 361 | 29561723 |
Orthostatic hypotension | 69.50 | 15.32 | 65 | 12378 | 22564 | 29539520 |
Parkinsonism | 68.49 | 15.32 | 41 | 12402 | 7237 | 29554847 |
Abnormal behaviour | 66.40 | 15.32 | 64 | 12379 | 23063 | 29539021 |
Delusion | 65.82 | 15.32 | 47 | 12396 | 11169 | 29550915 |
Obsessive-compulsive disorder | 62.73 | 15.32 | 33 | 12410 | 4543 | 29557541 |
Gait disturbance | 62.21 | 15.32 | 111 | 12332 | 73238 | 29488846 |
Dysphagia | 61.20 | 15.32 | 94 | 12349 | 54832 | 29507252 |
Therapeutic product effect variable | 58.75 | 15.32 | 24 | 12419 | 1853 | 29560231 |
Psychotic disorder | 57.81 | 15.32 | 56 | 12387 | 20298 | 29541786 |
Compulsive shopping | 57.29 | 15.32 | 16 | 12427 | 378 | 29561706 |
Delirium | 54.93 | 15.32 | 75 | 12368 | 39322 | 29522762 |
Paraphilia | 52.45 | 15.32 | 11 | 12432 | 71 | 29562013 |
Reduced facial expression | 52.11 | 15.32 | 17 | 12426 | 689 | 29561395 |
Jealous delusion | 51.98 | 15.32 | 13 | 12430 | 197 | 29561887 |
Agitation | 47.85 | 15.32 | 81 | 12362 | 51223 | 29510861 |
Diarrhoea | 47.81 | 15.32 | 42 | 12401 | 332656 | 29229428 |
Stoma site discharge | 47.75 | 15.32 | 17 | 12426 | 900 | 29561184 |
Dystonia | 46.34 | 15.32 | 36 | 12407 | 9713 | 29552371 |
Somnolence | 43.34 | 15.32 | 111 | 12332 | 93844 | 29468240 |
Aggression | 42.65 | 15.32 | 63 | 12380 | 35478 | 29526606 |
Hyperkinesia | 41.85 | 15.32 | 18 | 12425 | 1581 | 29560503 |
Stoma site erythema | 41.72 | 15.32 | 14 | 12429 | 620 | 29561464 |
Embedded device | 40.70 | 15.32 | 11 | 12432 | 229 | 29561855 |
Fibroma | 39.96 | 15.32 | 11 | 12432 | 246 | 29561838 |
Phlebitis infective | 36.99 | 15.32 | 9 | 12434 | 121 | 29561963 |
Saliva discolouration | 36.49 | 15.32 | 6 | 12437 | 6 | 29562078 |
Off label use | 34.27 | 15.32 | 46 | 12397 | 300754 | 29261330 |
Febrile neutropenia | 33.42 | 15.32 | 4 | 12439 | 112236 | 29449848 |
Cognitive disorder | 33.13 | 15.32 | 45 | 12398 | 23454 | 29538630 |
Libido increased | 32.44 | 15.32 | 12 | 12431 | 709 | 29561375 |
Restlessness | 32.13 | 15.32 | 43 | 12400 | 22102 | 29539982 |
Compulsive sexual behaviour | 31.59 | 15.32 | 9 | 12434 | 229 | 29561855 |
Marital problem | 31.43 | 15.32 | 7 | 12436 | 62 | 29562022 |
Device use issue | 31.22 | 15.32 | 9 | 12434 | 239 | 29561845 |
Persecutory delusion | 30.94 | 15.32 | 16 | 12427 | 2125 | 29559959 |
Obsessive-compulsive personality disorder | 30.65 | 15.32 | 8 | 12435 | 145 | 29561939 |
Stereotypy | 29.77 | 15.32 | 11 | 12432 | 648 | 29561436 |
Hypertonia | 29.51 | 15.32 | 19 | 12424 | 3810 | 29558274 |
Product cleaning inadequate | 29.10 | 15.32 | 5 | 12438 | 8 | 29562076 |
Device dislocation | 28.95 | 15.32 | 20 | 12423 | 4507 | 29557577 |
Compulsions | 28.93 | 15.32 | 8 | 12435 | 182 | 29561902 |
Mobility decreased | 28.51 | 15.32 | 44 | 12399 | 25736 | 29536348 |
Aortic valve incompetence | 27.11 | 15.32 | 20 | 12423 | 4993 | 29557091 |
Deep brain stimulation | 26.47 | 15.32 | 5 | 12438 | 17 | 29562067 |
Therapeutic response shortened | 25.65 | 15.32 | 19 | 12424 | 4772 | 29557312 |
Pneumonia aspiration | 25.39 | 15.32 | 51 | 12392 | 36686 | 29525398 |
Camptocormia | 25.28 | 15.32 | 7 | 12436 | 160 | 29561924 |
Pleurothotonus | 24.93 | 15.32 | 11 | 12432 | 1027 | 29561057 |
Speech disorder | 24.42 | 15.32 | 39 | 12404 | 23477 | 29538607 |
Platelet count decreased | 24.22 | 15.32 | 7 | 12436 | 104665 | 29457419 |
Motor dysfunction | 24.14 | 15.32 | 20 | 12423 | 5910 | 29556174 |
Tension | 23.98 | 15.32 | 13 | 12430 | 1900 | 29560184 |
Autonomic nervous system imbalance | 23.96 | 15.32 | 14 | 12429 | 2362 | 29559722 |
Impulsive behaviour | 23.79 | 15.32 | 13 | 12430 | 1930 | 29560154 |
Posture abnormal | 23.76 | 15.32 | 13 | 12430 | 1934 | 29560150 |
Binge eating | 23.63 | 15.32 | 6 | 12437 | 97 | 29561987 |
Product complaint | 23.62 | 15.32 | 19 | 12424 | 5386 | 29556698 |
Balance disorder | 23.56 | 15.32 | 49 | 12394 | 36121 | 29525963 |
Apathy | 23.44 | 15.32 | 20 | 12423 | 6151 | 29555933 |
Abnormal dreams | 23.42 | 15.32 | 21 | 12422 | 6899 | 29555185 |
Product residue present | 23.10 | 15.32 | 14 | 12429 | 2525 | 29559559 |
Extrapyramidal disorder | 22.13 | 15.32 | 25 | 12418 | 10806 | 29551278 |
Stoma site irritation | 21.72 | 15.32 | 6 | 12437 | 136 | 29561948 |
Disorientation | 21.63 | 15.32 | 42 | 12401 | 29473 | 29532611 |
Sleep attacks | 21.55 | 15.32 | 6 | 12437 | 140 | 29561944 |
Hyperthermia | 21.40 | 15.32 | 23 | 12420 | 9407 | 29552677 |
Device issue | 21.32 | 15.32 | 21 | 12422 | 7759 | 29554325 |
Depression | 20.99 | 15.32 | 81 | 12362 | 85066 | 29477018 |
Supine hypertension | 20.97 | 15.32 | 7 | 12436 | 305 | 29561779 |
Device difficult to use | 20.50 | 15.32 | 11 | 12432 | 1575 | 29560509 |
Pruritus | 20.30 | 15.32 | 12 | 12431 | 116837 | 29445247 |
Movement disorder | 19.85 | 15.32 | 23 | 12420 | 10214 | 29551870 |
Mesenteric artery thrombosis | 18.95 | 15.32 | 7 | 12436 | 412 | 29561672 |
Device occlusion | 18.94 | 15.32 | 17 | 12426 | 5591 | 29556493 |
Syncope | 18.91 | 15.32 | 76 | 12367 | 81295 | 29480789 |
Stoma site inflammation | 18.73 | 15.32 | 7 | 12436 | 426 | 29561658 |
Dependence | 18.70 | 15.32 | 9 | 12434 | 1026 | 29561058 |
Illusion | 18.69 | 15.32 | 8 | 12435 | 694 | 29561390 |
Psychomotor hyperactivity | 18.58 | 15.32 | 20 | 12423 | 8193 | 29553891 |
Neutropenia | 18.39 | 15.32 | 17 | 12426 | 131694 | 29430390 |
Wrong technique in device usage process | 18.29 | 15.32 | 9 | 12434 | 1076 | 29561008 |
Postural reflex impairment | 18.24 | 15.32 | 3 | 12440 | 3 | 29562081 |
Formication | 18.02 | 15.32 | 10 | 12433 | 1530 | 29560554 |
Choking | 17.97 | 15.32 | 15 | 12428 | 4476 | 29557608 |
Condition aggravated | 17.92 | 15.32 | 114 | 12329 | 146181 | 29415903 |
Micrographia | 17.03 | 15.32 | 3 | 12440 | 6 | 29562078 |
Economic problem | 17.02 | 15.32 | 9 | 12434 | 1251 | 29560833 |
Malignant neoplasm progression | 16.97 | 15.32 | 5 | 12438 | 73854 | 29488230 |
Anticholinergic syndrome | 16.84 | 15.32 | 8 | 12435 | 886 | 29561198 |
Progressive supranuclear palsy | 16.78 | 15.32 | 4 | 12439 | 49 | 29562035 |
Pancytopenia | 16.76 | 15.32 | 7 | 12436 | 83161 | 29478923 |
Memory impairment | 16.69 | 15.32 | 43 | 12400 | 36427 | 29525657 |
Stoma site reaction | 16.58 | 15.32 | 5 | 12438 | 156 | 29561928 |
General physical health deterioration | 16.41 | 15.32 | 86 | 12357 | 102771 | 29459313 |
Clonus | 16.38 | 15.32 | 11 | 12432 | 2367 | 29559717 |
Obsessive thoughts | 16.27 | 15.32 | 7 | 12436 | 615 | 29561469 |
Drug withdrawal syndrome | 16.22 | 15.32 | 28 | 12415 | 17956 | 29544128 |
Soft tissue mass | 16.12 | 15.32 | 7 | 12436 | 629 | 29561455 |
Sleep disorder | 15.83 | 15.32 | 33 | 12410 | 24353 | 29537731 |
Blood creatine phosphokinase increased | 15.67 | 15.32 | 45 | 12398 | 40599 | 29521485 |
Listless | 15.56 | 15.32 | 9 | 12434 | 1489 | 29560595 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dyskinesia | 552.93 | 14.12 | 255 | 18225 | 39133 | 64441119 |
Hallucination | 329.76 | 14.12 | 224 | 18256 | 72564 | 64407688 |
Dopamine dysregulation syndrome | 317.26 | 14.12 | 62 | 18418 | 417 | 64479835 |
On and off phenomenon | 306.99 | 14.12 | 82 | 18398 | 2437 | 64477815 |
Impulse-control disorder | 303.38 | 14.12 | 74 | 18406 | 1514 | 64478738 |
Hallucination, visual | 269.60 | 14.12 | 140 | 18340 | 27694 | 64452558 |
Muscle rigidity | 266.58 | 14.12 | 120 | 18360 | 17353 | 64462899 |
Gambling disorder | 261.16 | 14.12 | 68 | 18412 | 1826 | 64478426 |
Hypersexuality | 252.64 | 14.12 | 63 | 18417 | 1416 | 64478836 |
Parkinson's disease | 247.68 | 14.12 | 63 | 18417 | 1538 | 64478714 |
Neuroleptic malignant syndrome | 225.76 | 14.12 | 120 | 18360 | 24876 | 64455376 |
Bradykinesia | 167.31 | 14.12 | 65 | 18415 | 6495 | 64473757 |
Akinesia | 136.82 | 14.12 | 46 | 18434 | 3033 | 64477219 |
Parkinsonism | 129.72 | 14.12 | 69 | 18411 | 14304 | 64465948 |
Delusion | 128.34 | 14.12 | 74 | 18406 | 17940 | 64462312 |
Compulsive shopping | 122.27 | 14.12 | 31 | 18449 | 746 | 64479506 |
Tremor | 120.04 | 14.12 | 178 | 18302 | 148052 | 64332200 |
Fall | 119.93 | 14.12 | 324 | 18156 | 416502 | 64063750 |
Freezing phenomenon | 118.41 | 14.12 | 35 | 18445 | 1511 | 64478741 |
Dementia | 116.09 | 14.12 | 73 | 18407 | 20693 | 64459559 |
Delirium | 110.78 | 14.12 | 117 | 18363 | 69077 | 64411175 |
Pleurothotonus | 108.68 | 14.12 | 36 | 18444 | 2266 | 64477986 |
Dystonia | 102.16 | 14.12 | 65 | 18415 | 18800 | 64461452 |
Abnormal behaviour | 99.11 | 14.12 | 80 | 18400 | 33542 | 64446710 |
Therapeutic product effect variable | 90.98 | 14.12 | 29 | 18451 | 1615 | 64478637 |
Agitation | 90.72 | 14.12 | 119 | 18361 | 88248 | 64392004 |
Confusional state | 89.43 | 14.12 | 217 | 18263 | 260927 | 64219325 |
Orthostatic hypotension | 89.34 | 14.12 | 87 | 18393 | 46651 | 64433601 |
Reduced facial expression | 79.98 | 14.12 | 28 | 18452 | 2085 | 64478167 |
Torticollis | 75.37 | 14.12 | 27 | 18453 | 2150 | 64478102 |
Sudden onset of sleep | 75.21 | 14.12 | 20 | 18460 | 583 | 64479669 |
Stereotypy | 73.05 | 14.12 | 21 | 18459 | 821 | 64479431 |
Hyperkinesia | 71.25 | 14.12 | 27 | 18453 | 2519 | 64477733 |
Gait disturbance | 69.81 | 14.12 | 153 | 18327 | 172002 | 64308250 |
Gambling | 68.31 | 14.12 | 16 | 18464 | 273 | 64479979 |
Jealous delusion | 66.68 | 14.12 | 15 | 18465 | 212 | 64480040 |
Psychotic disorder | 65.39 | 14.12 | 64 | 18416 | 34514 | 64445738 |
Camptocormia | 65.00 | 14.12 | 17 | 18463 | 464 | 64479788 |
Aortic valve incompetence | 61.52 | 14.12 | 35 | 18445 | 8266 | 64471986 |
Diarrhoea | 58.45 | 14.12 | 73 | 18407 | 722631 | 63757621 |
Aggression | 58.21 | 14.12 | 69 | 18411 | 46163 | 64434089 |
Dysphagia | 57.70 | 14.12 | 107 | 18373 | 106705 | 64373547 |
Deep brain stimulation | 53.35 | 14.12 | 10 | 18470 | 52 | 64480200 |
Paraphilia | 52.88 | 14.12 | 10 | 18470 | 55 | 64480197 |
Therapeutic response shortened | 50.03 | 14.12 | 33 | 18447 | 10137 | 64470115 |
Restlessness | 49.46 | 14.12 | 59 | 18421 | 39726 | 64440526 |
Obsessive-compulsive disorder | 48.81 | 14.12 | 25 | 18455 | 4793 | 64475459 |
Drug withdrawal syndrome | 48.43 | 14.12 | 52 | 18428 | 31239 | 64449013 |
Somnolence | 48.32 | 14.12 | 148 | 18332 | 203497 | 64276755 |
Speech disorder | 47.77 | 14.12 | 64 | 18416 | 48377 | 64431875 |
Stoma site discharge | 47.66 | 14.12 | 18 | 18462 | 1664 | 64478588 |
Persecutory delusion | 46.29 | 14.12 | 23 | 18457 | 4135 | 64476117 |
Posture abnormal | 44.43 | 14.12 | 21 | 18459 | 3385 | 64476867 |
Blood creatine phosphokinase increased | 42.62 | 14.12 | 67 | 18413 | 58491 | 64421761 |
Pneumonia aspiration | 39.29 | 14.12 | 65 | 18415 | 59206 | 64421046 |
Disorientation | 38.05 | 14.12 | 62 | 18418 | 55766 | 64424486 |
Fibroma | 37.49 | 14.12 | 12 | 18468 | 677 | 64479575 |
Ileus | 37.01 | 14.12 | 39 | 18441 | 22927 | 64457325 |
Progressive supranuclear palsy | 36.26 | 14.12 | 8 | 18472 | 103 | 64480149 |
Rheumatoid arthritis | 35.87 | 14.12 | 3 | 18477 | 164291 | 64315961 |
Joint swelling | 35.46 | 14.12 | 9 | 18471 | 215373 | 64264879 |
Pruritus | 35.38 | 14.12 | 23 | 18457 | 312377 | 64167875 |
Dropped head syndrome | 34.76 | 14.12 | 9 | 18471 | 236 | 64480016 |
Febrile neutropenia | 34.67 | 14.12 | 6 | 18474 | 187651 | 64292601 |
Product complaint | 34.27 | 14.12 | 28 | 18452 | 11926 | 64468326 |
Peripheral swelling | 33.93 | 14.12 | 9 | 18471 | 209144 | 64271108 |
Binge eating | 33.64 | 14.12 | 10 | 18470 | 440 | 64479812 |
Drug interaction | 33.31 | 14.12 | 197 | 18283 | 361886 | 64118366 |
Tricuspid valve incompetence | 33.13 | 14.12 | 32 | 18448 | 16971 | 64463281 |
Off label use | 32.94 | 14.12 | 84 | 18396 | 632722 | 63847530 |
Myoclonus | 32.45 | 14.12 | 38 | 18442 | 25080 | 64455172 |
Hypertonia | 32.27 | 14.12 | 21 | 18459 | 6304 | 64473948 |
Cognitive disorder | 32.02 | 14.12 | 57 | 18423 | 55030 | 64425222 |
Stoma site pain | 31.65 | 14.12 | 12 | 18468 | 1121 | 64479131 |
Pain | 31.56 | 14.12 | 70 | 18410 | 553441 | 63926811 |
Apathy | 31.55 | 14.12 | 26 | 18454 | 11206 | 64469046 |
Vascular encephalopathy | 31.28 | 14.12 | 10 | 18470 | 562 | 64479690 |
Sinusitis | 30.95 | 14.12 | 3 | 18477 | 145925 | 64334327 |
Fatigue | 30.68 | 14.12 | 111 | 18369 | 748619 | 63731633 |
Product residue present | 30.48 | 14.12 | 16 | 18464 | 3226 | 64477026 |
Parkinsonism hyperpyrexia syndrome | 30.46 | 14.12 | 8 | 18472 | 222 | 64480030 |
Impulsive behaviour | 30.45 | 14.12 | 15 | 18465 | 2648 | 64477604 |
Oromandibular dystonia | 30.39 | 14.12 | 11 | 18469 | 902 | 64479350 |
Rash | 29.53 | 14.12 | 54 | 18426 | 458495 | 64021757 |
Autonomic nervous system imbalance | 29.49 | 14.12 | 17 | 18463 | 4115 | 64476137 |
Device use issue | 29.25 | 14.12 | 13 | 18467 | 1820 | 64478432 |
Drug hypersensitivity | 29.03 | 14.12 | 16 | 18464 | 237799 | 64242453 |
Eczema eyelids | 28.70 | 14.12 | 7 | 18473 | 143 | 64480109 |
Headache | 28.53 | 14.12 | 69 | 18411 | 529398 | 63950854 |
Tarsal tunnel syndrome | 28.32 | 14.12 | 9 | 18471 | 496 | 64479756 |
Stoma site reaction | 27.99 | 14.12 | 8 | 18472 | 306 | 64479946 |
Movement disorder | 27.95 | 14.12 | 33 | 18447 | 21967 | 64458285 |
Anxiety | 27.51 | 14.12 | 123 | 18357 | 202526 | 64277726 |
Cerebral atrophy | 27.29 | 14.12 | 20 | 18460 | 7265 | 64472987 |
Serotonin syndrome | 27.27 | 14.12 | 44 | 18436 | 39238 | 64441014 |
Stoma site erythema | 27.13 | 14.12 | 11 | 18469 | 1228 | 64479024 |
Mitral valve incompetence | 27.12 | 14.12 | 35 | 18445 | 25503 | 64454749 |
Urticaria | 26.58 | 14.12 | 5 | 18475 | 147312 | 64332940 |
Hypokinesia | 26.41 | 14.12 | 28 | 18452 | 16568 | 64463684 |
Stoma site irritation | 26.13 | 14.12 | 7 | 18473 | 210 | 64480042 |
Hyperthermia | 26.12 | 14.12 | 27 | 18453 | 15523 | 64464729 |
Extrapyramidal disorder | 25.96 | 14.12 | 30 | 18450 | 19522 | 64460730 |
Alopecia | 25.27 | 14.12 | 8 | 18472 | 165682 | 64314570 |
Paranoia | 24.99 | 14.12 | 27 | 18453 | 16325 | 64463927 |
Obsessive-compulsive personality disorder | 24.53 | 14.12 | 6 | 18474 | 124 | 64480128 |
Nasopharyngitis | 24.20 | 14.12 | 13 | 18467 | 196060 | 64284192 |
Purpura senile | 24.15 | 14.12 | 8 | 18472 | 503 | 64479749 |
Psychomotor hyperactivity | 24.10 | 14.12 | 25 | 18455 | 14426 | 64465826 |
Product use issue | 23.72 | 14.12 | 7 | 18473 | 151708 | 64328544 |
Product cleaning inadequate | 23.62 | 14.12 | 4 | 18476 | 10 | 64480242 |
Postural reflex impairment | 23.35 | 14.12 | 4 | 18476 | 11 | 64480241 |
Motor dysfunction | 23.28 | 14.12 | 22 | 18458 | 11351 | 64468901 |
Retroperitoneal fibrosis | 23.23 | 14.12 | 8 | 18472 | 567 | 64479685 |
Depressed level of consciousness | 22.95 | 14.12 | 63 | 18417 | 81373 | 64398879 |
Compulsions | 22.90 | 14.12 | 7 | 18473 | 339 | 64479913 |
Abdominal discomfort | 22.63 | 14.12 | 12 | 18468 | 182310 | 64297942 |
Supine hypertension | 22.61 | 14.12 | 7 | 18473 | 354 | 64479898 |
Resting tremor | 22.47 | 14.12 | 10 | 18470 | 1404 | 64478848 |
Arthralgia | 21.98 | 14.12 | 60 | 18420 | 442200 | 64038052 |
Mania | 21.64 | 14.12 | 25 | 18455 | 16261 | 64463991 |
Dementia with Lewy bodies | 21.61 | 14.12 | 8 | 18472 | 699 | 64479553 |
Aortic valve sclerosis | 21.41 | 14.12 | 10 | 18470 | 1569 | 64478683 |
Marital problem | 21.37 | 14.12 | 6 | 18474 | 215 | 64480037 |
Ketonuria | 21.35 | 14.12 | 9 | 18471 | 1108 | 64479144 |
Orthostatic intolerance | 21.29 | 14.12 | 10 | 18470 | 1590 | 64478662 |
Resorption bone increased | 20.96 | 14.12 | 9 | 18471 | 1159 | 64479093 |
Kleptomania | 20.72 | 14.12 | 4 | 18476 | 25 | 64480227 |
Syncope | 20.13 | 14.12 | 94 | 18386 | 157541 | 64322711 |
Withdrawal syndrome | 20.10 | 14.12 | 29 | 18451 | 23463 | 64456789 |
Pancytopenia | 20.01 | 14.12 | 8 | 18472 | 143301 | 64336951 |
Mesenteric artery thrombosis | 19.78 | 14.12 | 7 | 18473 | 538 | 64479714 |
Platelet count decreased | 19.44 | 14.12 | 12 | 18468 | 167699 | 64312553 |
Stoma site inflammation | 19.42 | 14.12 | 7 | 18473 | 567 | 64479685 |
Swelling | 19.22 | 14.12 | 11 | 18469 | 160207 | 64320045 |
Heat stroke | 19.07 | 14.12 | 9 | 18471 | 1446 | 64478806 |
Choking | 18.98 | 14.12 | 19 | 18461 | 10519 | 64469733 |
Hyperreflexia | 18.95 | 14.12 | 16 | 18464 | 7132 | 64473120 |
Formication | 18.71 | 14.12 | 13 | 18467 | 4344 | 64475908 |
Delusion of replacement | 18.66 | 14.12 | 5 | 18475 | 150 | 64480102 |
Hepatic enzyme increased | 18.56 | 14.12 | 7 | 18473 | 129936 | 64350316 |
Drug intolerance | 18.48 | 14.12 | 16 | 18464 | 187976 | 64292276 |
Cogwheel rigidity | 18.42 | 14.12 | 11 | 18469 | 2842 | 64477410 |
Balance disorder | 18.04 | 14.12 | 59 | 18421 | 83867 | 64396385 |
Sleep attacks | 17.81 | 14.12 | 5 | 18475 | 179 | 64480073 |
Dysarthria | 17.78 | 14.12 | 47 | 18433 | 59359 | 64420893 |
Tension | 17.78 | 14.12 | 12 | 18468 | 3828 | 64476424 |
Asthma | 17.68 | 14.12 | 3 | 18477 | 95222 | 64385030 |
Electrocardiogram J wave | 17.56 | 14.12 | 4 | 18476 | 60 | 64480192 |
Lower respiratory tract infection | 17.52 | 14.12 | 3 | 18477 | 94611 | 64385641 |
Ballismus | 17.35 | 14.12 | 5 | 18475 | 197 | 64480055 |
Medical device site scab | 17.32 | 14.12 | 3 | 18477 | 9 | 64480243 |
Dermatillomania | 17.30 | 14.12 | 5 | 18475 | 199 | 64480053 |
Libido increased | 17.30 | 14.12 | 9 | 18471 | 1781 | 64478471 |
Oral discomfort | 16.71 | 14.12 | 16 | 18464 | 8390 | 64471862 |
Infection | 16.69 | 14.12 | 17 | 18463 | 184863 | 64295389 |
Mitral valve disease | 16.58 | 14.12 | 10 | 18470 | 2628 | 64477624 |
Neutropenia | 16.51 | 14.12 | 27 | 18453 | 239597 | 64240655 |
Device dislocation | 16.47 | 14.12 | 25 | 18455 | 21153 | 64459099 |
Device difficult to use | 16.43 | 14.12 | 17 | 18463 | 9781 | 64470471 |
Chorea | 16.36 | 14.12 | 9 | 18471 | 1991 | 64478261 |
Soft tissue mass | 16.30 | 14.12 | 7 | 18473 | 902 | 64479350 |
Coronary artery dissection | 16.29 | 14.12 | 7 | 18473 | 903 | 64479349 |
Femoral neck fracture | 16.21 | 14.12 | 16 | 18464 | 8708 | 64471544 |
Hallucination, auditory | 16.11 | 14.12 | 22 | 18458 | 16917 | 64463335 |
Nuchal rigidity | 15.97 | 14.12 | 7 | 18473 | 948 | 64479304 |
Abnormal dreams | 15.65 | 14.12 | 17 | 18463 | 10339 | 64469913 |
Hypersensitivity | 15.63 | 14.12 | 20 | 18460 | 196432 | 64283820 |
Obsessive thoughts | 15.55 | 14.12 | 7 | 18473 | 1010 | 64479242 |
Treatment failure | 15.54 | 14.12 | 7 | 18473 | 116809 | 64363443 |
Granulocytopenia | 15.53 | 14.12 | 17 | 18463 | 10423 | 64469829 |
Mobility decreased | 15.53 | 14.12 | 57 | 18423 | 85783 | 64394469 |
Stomatitis | 15.49 | 14.12 | 6 | 18474 | 109599 | 64370653 |
Illusion | 15.48 | 14.12 | 8 | 18472 | 1562 | 64478690 |
Device issue | 15.22 | 14.12 | 25 | 18455 | 22623 | 64457629 |
Vestibular disorder | 15.22 | 14.12 | 9 | 18471 | 2284 | 64477968 |
Condition aggravated | 15.06 | 14.12 | 168 | 18312 | 372258 | 64107994 |
Subileus | 14.99 | 14.12 | 12 | 18468 | 4965 | 64475287 |
Micturition disorder | 14.96 | 14.12 | 10 | 18470 | 3138 | 64477114 |
Dyspnoea | 14.92 | 14.12 | 133 | 18347 | 718541 | 63761711 |
Influenza | 14.78 | 14.12 | 6 | 18474 | 106525 | 64373727 |
Malignant neoplasm progression | 14.64 | 14.12 | 7 | 18473 | 112864 | 64367388 |
Sudden death | 14.62 | 14.12 | 23 | 18457 | 20073 | 64460179 |
Nocturia | 14.60 | 14.12 | 17 | 18463 | 11148 | 64469104 |
Pyrexia | 14.59 | 14.12 | 97 | 18383 | 558547 | 63921705 |
Listless | 14.56 | 14.12 | 10 | 18470 | 3280 | 64476972 |
Altered state of consciousness | 14.55 | 14.12 | 33 | 18447 | 37869 | 64442383 |
Device occlusion | 14.50 | 14.12 | 16 | 18464 | 9897 | 64470355 |
Cross sensitivity reaction | 14.35 | 14.12 | 10 | 18470 | 3357 | 64476895 |
Yawning | 14.35 | 14.12 | 7 | 18473 | 1209 | 64479043 |
Injection site pain | 14.32 | 14.12 | 7 | 18473 | 111401 | 64368851 |
Gait inability | 14.22 | 14.12 | 35 | 18445 | 42333 | 64437919 |
Product physical issue | 14.14 | 14.12 | 10 | 18470 | 3439 | 64476813 |
None
Source | Code | Description |
---|---|---|
ATC | N04BA01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopa and dopa derivatives |
ATC | N04BA02 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopa and dopa derivatives |
ATC | N04BA03 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopa and dopa derivatives |
FDA CS | M0003647 | Catecholamines |
FDA CS | M0370111 | Amino Acids, Aromatic |
FDA EPC | N0000175570 | Catecholamine |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D013566 | Sympathomimetics |
MeSH PA | D018726 | Anti-Dyskinesia Agents |
MeSH PA | D000978 | Antiparkinson Agents |
MeSH PA | D002491 | Central Nervous System Agents |
FDA EPC | N0000193220 | Aromatic Amino Acid |
CHEBI has role | CHEBI:35219 | plant growth inhibitors |
CHEBI has role | CHEBI:48407 | antiparkinson agent |
CHEBI has role | CHEBI:48560 | dopaminergic agents |
CHEBI has role | CHEBI:50266 | Prodrugs |
CHEBI has role | CHEBI:50910 | agente neurotoxico |
CHEBI has role | CHEBI:59174 | haptens |
CHEBI has role | CHEBI:62215 | allelochemicals |
CHEBI has role | CHEBI:66956 | antidyskinetic agent |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
CHEBI has role | CHEBI:35524 | sympathomimetic |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Postencephalitic parkinsonism | indication | 19972008 | DOID:14332 |
Parkinsonism | indication | 32798002 | |
Parkinson's disease | indication | 49049000 | DOID:14330 |
Restless legs | off-label use | 32914008 | DOID:0050425 |
Age-related macular degeneration | off-label use | 267718000 | DOID:10871 |
Suicidal thoughts | contraindication | 6471006 | |
Hallucinations | contraindication | 7011001 | |
Dyskinesia | contraindication | 9748009 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Orthostatic hypotension | contraindication | 28651003 | |
Obstruction of bile duct | contraindication | 30144000 | |
Depressive disorder | contraindication | 35489007 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Duodenal ulcer disease | contraindication | 51868009 | DOID:1724 |
Diarrhea | contraindication | 62315008 | |
Psychotic disorder | contraindication | 69322001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Acute disease of cardiovascular system | contraindication | 128487001 | |
Seizure disorder | contraindication | 128613002 | |
Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Retention of urine | contraindication | 267064002 | |
Psychoneurotic personality disorder | contraindication | 268634009 | |
Malignant melanoma | contraindication | 372244006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Cardiovascular event risk | contraindication | 395112001 | |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.31 | acidic |
pKa2 | 9.07 | acidic |
pKa3 | 13.05 | acidic |
pKa4 | 10.01 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7094427 | May 29, 2022 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7094427 | May 29, 2022 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7094427 | May 29, 2022 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7094427 | May 29, 2022 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
42MG | INBRIJA | ACORDA | N209184 | Dec. 21, 2018 | RX | POWDER | INHALATION | 8404276 | March 19, 2023 | INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES |
42MG | INBRIJA | ACORDA | N209184 | Dec. 21, 2018 | RX | POWDER | INHALATION | 8586093 | March 19, 2023 | INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
23.75MG;95MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
36.25MG;145MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
48.75MG;195MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
61.25MG;245MG | RYTARY | IMPAX LABS INC | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
42MG | INBRIJA | ACORDA | N209184 | Dec. 21, 2018 | RX | POWDER | INHALATION | RE43711 | Feb. 3, 2029 | INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES |
25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11033521 | March 28, 2039 | METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG |
25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11033521 | March 28, 2039 | METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG, EACH SEGMENT HAVING CARBIDOPA—6.25 MG/LEVODOPA—25 MG |
25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11033521 | March 28, 2039 | TREATMENT OF PARKINSONS DISEASE |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
4.63MG/ML;20MG/ML | DUOPA | ABBVIE INC | N203952 | Jan. 9, 2015 | RX | SUSPENSION | ENTERAL | Jan. 9, 2022 | TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSONS DISEASE |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(1A) dopamine receptor | GPCR | AGONIST | WOMBAT-PK | SCIENTIFIC LITERATURE | |||||
D(2) dopamine receptor | GPCR | AGONIST | WOMBAT-PK | SCIENTIFIC LITERATURE | |||||
Tyrosine-protein kinase Lck | Kinase | IC50 | 5.43 | DRUG MATRIX | |||||
Large neutral amino acids transporter small subunit 1 | Transporter | IC50 | 4 | CHEMBL | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.67 | DRUG MATRIX | |||||
Epidermal growth factor receptor | Kinase | IC50 | 5.54 | DRUG MATRIX | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.65 | DRUG MATRIX |
ID | Source |
---|---|
4017790 | VUID |
N0000146151 | NUI |
D00059 | KEGG_DRUG |
4017790 | VANDF |
4019733 | VANDF |
C0023570 | UMLSCUI |
CHEBI:15765 | CHEBI |
CHEBI:18243 | CHEBI |
TY3 | PDB_CHEM_ID |
LDP | PDB_CHEM_ID |
CHEMBL1009 | ChEMBL_ID |
DB01235 | DRUGBANK_ID |
D007980 | MESH_DESCRIPTOR_UI |
6047 | PUBCHEM_CID |
2651 | INN_ID |
3639 | IUPHAR_LIGAND_ID |
46627O600J | UNII |
DB00988 | DRUGBANK_ID |
3628 | RXNORM |
1804 | MMSL |
4971 | MMSL |
6641 | MMSL |
d00216 | MMSL |
d00277 | MMSL |
001639 | NDDF |
004721 | NDDF |
15383004 | SNOMEDCT_US |
387086006 | SNOMEDCT_US |
412383006 | SNOMEDCT_US |
59187003 | SNOMEDCT_US |
65955006 | SNOMEDCT_US |
D004295 | MESH_DESCRIPTOR_UI |
681 | PUBCHEM_CID |
C0013030 | UMLSCUI |
D004298 | MESH_DESCRIPTOR_UI |
2417 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SINEMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-3915 | TABLET | 100 mg | ORAL | NDA | 25 sections |
SINEMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-3916 | TABLET | 100 mg | ORAL | NDA | 25 sections |
SINEMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-3917 | TABLET | 250 mg | ORAL | NDA | 25 sections |
SINEMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-6722 | TABLET | 100 mg | ORAL | NDA | 25 sections |
SINEMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-6723 | TABLET | 250 mg | ORAL | NDA | 25 sections |
SINEMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-6724 | TABLET | 100 mg | ORAL | NDA | 25 sections |
Duopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-3012 | SUSPENSION | 20 mg | ENTERAL | NDA | 31 sections |
Duopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-3012 | SUSPENSION | 20 mg | ENTERAL | NDA | 31 sections |
Stalevo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0078-0407 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 25 sections |
Stalevo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0078-0408 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 25 sections |
Stalevo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0078-0409 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 25 sections |
Stalevo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0078-0527 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 25 sections |
Stalevo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0078-0544 | TABLET, FILM COATED | 75 mg | ORAL | NDA | 25 sections |
Stalevo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0078-0545 | TABLET, FILM COATED | 125 mg | ORAL | NDA | 25 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9701 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9701 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9702 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9702 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2538 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2538 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2539 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2539 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2540 | TABLET | 250 mg | ORAL | ANDA | 11 sections |
Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2540 | TABLET | 250 mg | ORAL | ANDA | 11 sections |
Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0078 | TABLET | 100 mg | ORAL | ANDA | 24 sections |
Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0085 | TABLET | 100 mg | ORAL | ANDA | 24 sections |
Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0088 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 24 sections |
Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0094 | TABLET, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 24 sections |
Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-1133 | TABLET | 250 mg | ORAL | ANDA | 24 sections |
Carbidopa, Levodopa and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0378-8300 | TABLET, FILM COATED | 50 mg | ORAL | NDA authorized generic | 24 sections |